Metabolic diseases present particular difficulty for clinicians because they are often present for years before becoming clinically apparent. Clinical predictors of future diabetes mellitus (DM) are imperfect. The identification of individuals at ris is of particular importance because the delay or prevention of type 2 DM is possible via both behavioral and pharmacological interventions. In the first 3 1/2 years of this grant, we applied our mass spectrometry-based metabolomics platform to identify and validate metabolite profiles of those destined to develop overt DM. The findings were based on longitudinal follow-up in two prospective cohorts, the Framingham Heart Study and the Malmo Diet and Cancer Study. The strongest individual predictors of future DM included branched chain amino acids, aromatic amino acids, and 2-aminoadipic acid (a lysine degradation product). These metabolites were elevated up to 12 years before the onset of DM in glucose-tolerant individuals at baseline, and predicted DM above and beyond clinical risk factors and biochemical markers. These findings suggest that metabolite profiling could play a role in DM prevention strategies. To test this hypothesis, we will leverage the unique resources of the Diabetes Prevention Program (DPP), a multi-center RCT of interventions to prevent or delay the onset of DM in individuals at high-risk of the disease.
In Aim 1, we will assess the relation of baseline metabolites with incident DM, and test interactions of metabolites with therapy.
In Aim 2, we will determine whether lifestyle and pharmacologic interventions lead to changes in selected metabolites.
In Aim 3, we will investigate relations of metabolites with insulin sensitivity and insulin secretion measures. We will perform cross-sectional and longitudinal analyses to investigate the relation of metabolites with measures of insulin sensitivity and secretion. The DPP represents an ideal setting in which to conduct the investigations for the next phase of our grant, examining novel predictors of DM and their potential role in personalizing therapeutic interventions.

Public Health Relevance

Current treatments for diabetes mellitus (DM) are only partially successful, in part because they are based on limited knowledge of its root causes. Furthermore, there is no way to accurately predict who will develop DM, thus limiting our ability to intervene effectively. Our goal is to use new blood chemical profiling approaches to illuminate our understanding of the underlying disease mechanisms in DM, to identify novel predictors of DM, and to evaluate whether the predictors can help to personalize therapeutic interventions.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-N (M8))
Program Officer
Castle, Arthur
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Mayers, Jared R; Wu, Chen; Clish, Clary B et al. (2014) Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med 20:1193-8
Walford, Geoffrey A; Porneala, Bianca C; Dauriz, Marco et al. (2014) Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care 37:2508-14
Turer, Aslan T; Lewis, Gregory D; O'Sullivan, John F et al. (2014) Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. PLoS One 9:e99058
Roberts, Lee D; Boström, Pontus; O'Sullivan, John F et al. (2014) ?-Aminoisobutyric acid induces browning of white fat and hepatic ?-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab 19:96-108
Magnusson, Martin; Lewis, Gregory D; Ericson, Ulrika et al. (2013) A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J 34:1982-9
Wang, Thomas J; Ngo, Debby; Psychogios, Nikolaos et al. (2013) 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest 123:4309-17
Rhee, Eugene P; Clish, Clary B; Ghorbani, Anahita et al. (2013) A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 24:1330-8
Ho, Jennifer E; Larson, Martin G; Vasan, Ramachandran S et al. (2013) Metabolite profiles during oral glucose challenge. Diabetes 62:2689-98
Ganda, Anjali; Magnusson, Martin; Yvan-Charvet, Laurent et al. (2013) Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation 127:988-96
McCormack, S E; Shaham, O; McCarthy, M A et al. (2013) Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes 8:52-61

Showing the most recent 10 out of 30 publications